AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28367694 — intervention group
Group type: COMPARATOR
Intervention: MTPJ arthroplasty
Number of subjects: 52
Study 27465676 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy added to standard treatment (repositioning and an orthotic helmet)
Number of subjects: 46
Study 27465676 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (repositioning and an orthotic helmet)
Number of subjects: 46
Study 27465676 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy added to standard treatment
Number of subjects: 46
Study 24854418 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 265
Study 22055763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense weekly paclitaxel (ddT) plus carboplatin
Number of subjects: 0
Study 22055763 — intervention group
Group type: COMPARATOR
Intervention: Every-3-week paclitaxel (q3T) plus carboplatin
Number of subjects: 0
Study 22055763 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy including treatment administration (ddT)
Number of subjects: 0
Study 22055763 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy including treatment administration (q3T)
Number of subjects: 0
Study 19578177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) patients
Number of subjects: 36
Study 19578177 — intervention group
Group type: COMPARATOR
Intervention: Controls without heart failure
Number of subjects: 36
Study 19578177 — intervention group
Group type: EXPERIMENTAL
Intervention: AVD shortening in CRT patients
Number of subjects: 36
Study 19578177 — intervention group
Group type: EXPERIMENTAL
Intervention: AVD prolongation in CRT patients
Number of subjects: 36
Study 17452935 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 2640
Study 17452935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2640
Study 14693625 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine (0.2 mg/kg)
Number of subjects: 40
Study 14693625 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study 12563568 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg)
Number of subjects: 28
Study 12563568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9823811 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative drainage
Number of subjects: 40
Study 9823811 — intervention group
Group type: COMPARATOR
Intervention: No postoperative drainage
Number of subjects: 40
Study 7859550 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocation of money to characters described as friends
Number of subjects: 0
Study 7859550 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocation of money to characters described as strangers
Number of subjects: 0
Study 7859550 — intervention group
Group type: COMPARATOR
Intervention: Allocations and fairness ratings by kindergartners
Number of subjects: 0
Study 7859550 — intervention group
Group type: EXPERIMENTAL
Intervention: Rationales for allocation judgments
Number of subjects: 0
Study 2569730 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol
Number of subjects: 10
Study 2569730 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 10
Study 1067277 — intervention group
Group type: EXPERIMENTAL
Intervention: multitufted nylon brush
Number of subjects: 21
Study 1067277 — intervention group
Group type: EXPERIMENTAL
Intervention: wooden toothpick
Number of subjects: 21
Study 1067277 — intervention group
Group type: EXPERIMENTAL
Intervention: unwaxed dental floss
Number of subjects: 21
Study 1067277 — intervention group
Group type: EXPERIMENTAL
Intervention: combined cleaning exercise with all three instruments
Number of subjects: 21
Study 1067277 — intervention group
Group type: COMPARATOR
Intervention: none
Number of subjects: 21
Study 31081593 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors or SGLT-1/2 inhibitors as adjunct to insulin
Number of subjects: 0
Study 31081593 — intervention group
Group type: COMPARATOR
Intervention: SGLT-2 inhibitors or SGLT-1/2 inhibitors
Number of subjects: 0
Study 28566897 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet (LFD)
Number of subjects: 89
Study 28566897 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (ND)
Number of subjects: 89
Study 25819949 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive neurostimulation
Number of subjects: 191
Study 25819949 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 191
Study 23347236 — intervention group
Group type: EXPERIMENTAL
Intervention: Early subjective response (SR)
Number of subjects: 113
Study 23347236 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired tolerance
Number of subjects: 113
Study 21091369 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketorolac plus iliac crest normal saline infusion
Number of subjects: 54
Study 21091369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac plus iliac crest bupivacaine infusion
Number of subjects: 54
Study 21091369 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest bupivacaine infusion alone
Number of subjects: 54
Study 19107130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (17-item patient-completed continuity assessment and feedback to clinical nurse specialists)
Number of subjects: 61
Study 19107130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (feedback from continuity assessment to clinicians)
Number of subjects: 61
Study 19107130 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly defined in the abstract)
Number of subjects: 61
Study 17227568 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination pretransplant and lamivudine posttransplant for anti‐HBc(+) grafts for about 2 years
Number of subjects: 60
Study 14706436 — intervention group
Group type: EXPERIMENTAL
Intervention: 100g amino acid drink with tryptophan
Number of subjects: 14
Study 14706436 — intervention group
Group type: COMPARATOR
Intervention: 100g amino acid drink without tryptophan
Number of subjects: 14
Study 11597291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (up to 10 mg/d, n = 2837)
Number of subjects: 5720
Study 11597291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 2883)
Number of subjects: 5720
Study 11597291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (up to 10 mg/d)
Number of subjects: 5720
Study 9439401 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP laser bladder neck incision (BNI) with Nd:YAG endoscopic ablation (ELAP)
Number of subjects: 88
Study 9439401 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG endoscopic ablation (ELAP) alone
Number of subjects: 88
Study 9439401 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (KTP BNI + ELAP and ELAP alone)
Number of subjects: 88
Study 1790748 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.1% eye drops, applied twice daily for one week before surgery
Number of subjects: 60
Study 1790748 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% eye drops, applied twice daily for one week before surgery
Number of subjects: 60
Study 1790748 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops, applied twice daily for one week before surgery
Number of subjects: 60
Study 6803819 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (800 mg/day in the first week, 1 g/day in the second week)
Number of subjects: 10
Study 6803819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30037560 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended dwell catheter (EDC), 6 cm 3 French (19.5 gauge) Access Scientific POWERWAND™
Number of subjects: 120
Study 30037560 — intervention group
Group type: COMPARATOR
Intervention: Standard long IV catheter, 4.78 cm 20 gauge Becton Dickinson (BD)
Number of subjects: 120
Study 30037560 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended dwell catheter (EDC)
Number of subjects: 120
Study 27887881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with daily wake up
Number of subjects: 36
Study 27887881 — intervention group
Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 36
Study 25171906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (AUA-SI 8 or greater) in participants with BMI ≥ 30 kg/m²
Number of subjects: 4144
Study 25171906 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage score of 4 or greater in participants with BMI ≥ 30 kg/m²
Number of subjects: 4144
Study 25171906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (AUA-SI 8 or greater) in participants with abdominal obesity
Number of subjects: 4144
Study 25171906 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage score of 4 or greater in participants with abdominal obesity
Number of subjects: 4144
Study 25171906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (AUA-SI 8 or greater) in men and women younger than 50 years
Number of subjects: 4144
Study 23621572 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-layered covered SEMS
Number of subjects: 62
Study 23621572 — intervention group
Group type: COMPARATOR
Intervention: Uncovered SEMS
Number of subjects: 62
Study 21495914 — intervention group
Group type: EXPERIMENTAL
Intervention: Neater Uni‐Wheelchair (NUW) kit attachment
Number of subjects: 20
Study 21495914 — intervention group
Group type: COMPARATOR
Intervention: Standard Action 3 wheelchair
Number of subjects: 20
Study 20973685 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin 2 mg/hour
Number of subjects: 10
Study 20973685 — intervention group
Group type: COMPARATOR
Intervention: Heparin 400 units/hour
Number of subjects: 10
Study 20973685 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 10
Study 18621591 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg trazodone tablet formulation
Number of subjects: 36
Study 15928463 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 minutes of chest compressions prior to defibrillation
Number of subjects: 0
Study 15928463 — intervention group
Group type: COMPARATOR
Intervention: Immediate defibrillation
Number of subjects: 0
Study 12119515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloric drainage (pyloroplasty or pyloromyotomy)
Number of subjects: 553
Study 12119515 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 553
Study 10347132 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b, 3 million units three times per week for 48 weeks
Number of subjects: 99
Study 10347132 — intervention group
Group type: COMPARATOR
Intervention: No antiviral therapy (Control)
Number of subjects: 99
Study 10347132 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 99
Study 8817829 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (Engerix‐B, 10 micrograms dose‐1)
Number of subjects: 5000
Study 8817829 — intervention group
Group type: COMPARATOR
Intervention: Haemophilus influenzae type b (Hib) conjugate vaccine
Number of subjects: 5000
Study 1307052 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpinia speciosa
Number of subjects: 10
Study 4054192 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 4054192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31005923 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 64
Study 31005923 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 64
Study 28843031 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) prescribed to individuals scoring over 13 points on FINDRISC; 2.8% of population survey and 75.4% of opportunistic survey participants took the OGTT.
Number of subjects: 3759
Study 28843031 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels measured in participants with normal glucose tolerance, prediabetes, and T2D.
Number of subjects: 3759
Study 28843031 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of lipid profiles in participants with prediabetes and T2D.
Number of subjects: 3759
Study 28843031 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of insulin resistance in individuals with prediabetes.
Number of subjects: 3759
Study 26823294 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 81
Study 26823294 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 81
Study 24952057 — intervention group
Group type: EXPERIMENTAL
Intervention: FemoSeal VCD
Number of subjects: 4500
Study 24952057 — intervention group
Group type: EXPERIMENTAL
Intervention: EXOSEAL VCD
Number of subjects: 4500
Study 24952057 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 4500
Study 21848980 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium chloride 12.5%
Number of subjects: 20
Study 21848980 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium chloride 30%
Number of subjects: 20
Study 20071440 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV disclosure in Northern Thailand
Number of subjects: 410
Study 20071440 — intervention group
Group type: COMPARATOR
Intervention: HIV disclosure in Northeastern Thailand
Number of subjects: 410
Study 17584825 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with 5-fluorouracil
Number of subjects: 160
Study 17584825 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with S-1
Number of subjects: 160
Study 17584825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen (specifics not provided)
Number of subjects: 160
Study 17584825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimen (specifics not provided)
Number of subjects: 160
Study 17584825 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study 16132888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation with lower tidal volume (V(T) of 6 ml/kg ideal body weight)
Number of subjects: 44
Study 16132888 — intervention group
Group type: COMPARATOR
Intervention: Ventilation with higher tidal volume (V(T) of 12 ml/kg ideal body weight)
Number of subjects: 44
Study 16132888 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower tidal volume ventilation
Number of subjects: 44
Study 16132888 — intervention group
Group type: COMPARATOR
Intervention: Higher tidal volume ventilation
Number of subjects: 44
Study 12034024 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2a (3 x 10(6) IU) three times weekly for 8-16 weeks
Number of subjects: 44
Study 12034024 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2a (1.5-6 x 10(6) IU) three times weekly for 12 months
Number of subjects: 44
Study 12034024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12034024 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2a re-administration after discontinuation
Number of subjects: 44
Study 12034024 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha2a treatment
Number of subjects: 44
Study 10462652 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-knife fistulotomy
Number of subjects: 103
Study 10462652 — intervention group
Group type: COMPARATOR
Intervention: Needle-knife precut papillotomy
Number of subjects: 103
Study 8703666 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP (10 pmol kg‐1 min‐1)
Number of subjects: 8
Study 8703666 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP (10 pmol kg‐1 min‐1)
Number of subjects: 8
Study 8703666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 8
Study 2147175 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/day) for 36 weeks followed by a placebo period of 4 weeks
Number of subjects: 47
Study 2147175 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated fish oil (9 g/day) for 36 weeks with a subsequent period of 4 weeks in which fish oil placebo was given
Number of subjects: 47
Study 2147175 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/day) for 12 weeks, propranolol plus fish oil capsules (9 g/day) for 12 weeks, propranolol plus fish oil placebo for 12 weeks
Number of subjects: 47
Study 2147175 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 47
Study 6972101 — intervention group
Group type: EXPERIMENTAL
Intervention: Antrafenine 450 mg/day
Number of subjects: 14
Study 6972101 — intervention group
Group type: EXPERIMENTAL
Intervention: Antrafenine 900 mg/day
Number of subjects: 14
Study 6972101 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1.8 g/day
Number of subjects: 14
Study 6972101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31046719 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance plus balance training (twice weekly over 12 weeks)
Number of subjects: 50
Study 31046719 — intervention group
Group type: COMPARATOR
Intervention: Endurance training (twice weekly over 12 weeks)
Number of subjects: 50
Study 31046719 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance plus balance training
Number of subjects: 50
Study 31046719 — intervention group
Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 50
Study 28874595 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual funds plus additional funds (ranging from $6,750 to $234,000 AUD)
Number of subjects: 34
Study 28874595 — intervention group
Group type: COMPARATOR
Intervention: Usual CTMS funds
Number of subjects: 34
Study 28874595 — intervention group
Group type: COMPARATOR
Intervention: Intervention sites compared to control sites
Number of subjects: 34
Study 25979300 — intervention group
Group type: EXPERIMENTAL
Intervention: RIFL video laryngoscope
Number of subjects: 132
Study 25979300 — intervention group
Group type: COMPARATOR
Intervention: Miller laryngoscope
Number of subjects: 132
Study 23644816 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone based cognitive behavioral therapy (T-CBT)
Number of subjects: 34
Study 23644816 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face therapy (f2f)
Number of subjects: 34
Study 22852117 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 1000 mg twice daily
Number of subjects: 15
Study 22852117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19674861 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional intelligence developmental training workshops
Number of subjects: 86
Study 19674861 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 86
Study 15923279 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon particles (50 microg/m3)
Number of subjects: 0
Study 15923279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphur dioxide (200 ppb)
Number of subjects: 0
Study 15923279 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 0
Study 15923279 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon particles and SO2
Number of subjects: 0
Study 15526058 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA ME-TRAP followed by MVA ME-TRAP
Number of subjects: 372
Study 15526058 — intervention group
Group type: COMPARATOR
Intervention: rabies vaccine (control)
Number of subjects: 372
Study 11251139 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2%, 0.5 mL) mixed with radiopaque fluid (0.25 mL) injected after verifying target location using sensory and motor electrostimulation.
Number of subjects: 29
Study 11251139 — intervention group
Group type: COMPARATOR
Intervention: Standard dermatomal map
Number of subjects: 29
Study 11251139 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted dermatomal map
Number of subjects: 29
Study 9684395 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (referral to treatment)
Number of subjects: 0
Study 9684395 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reduction intervention
Number of subjects: 0
Study 9684395 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no HIS program)
Number of subjects: 0
Study 8162672 — intervention group
Group type: EXPERIMENTAL
Intervention: bretazenil
Number of subjects: 28
Study 8162672 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 28
Study 8162672 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 28
Study 8162672 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 3369999 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% apraclonidine hydrochloride
Number of subjects: 63
Study 3369999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 31944812 — intervention group
Group type: EXPERIMENTAL
Intervention: Downward temporal comparisons
Number of subjects: 583
Study 31944812 — intervention group
Group type: EXPERIMENTAL
Intervention: Downward social comparisons
Number of subjects: 583
Study 31944812 — intervention group
Group type: COMPARATOR
Intervention: Upward social comparisons
Number of subjects: 583
Study 31944812 — intervention group
Group type: COMPARATOR
Intervention: Upward temporal comparisons
Number of subjects: 583
Study 31944812 — intervention group
Group type: COMPARATOR
Intervention: No comparison
Number of subjects: 583
Study 29987027 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment protocol (3.5 days)
Number of subjects: 14
Study 29987027 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (3 days)
Number of subjects: 14
Study 29987027 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian misalignment protocol
Number of subjects: 14
Study 27793135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement augmented locking plate Philos™
Number of subjects: 40
Study 27793135 — intervention group
Group type: COMPARATOR
Intervention: Proximal humerus nail MultiLoc®
Number of subjects: 40
Study 25703058 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel cuff applied to the most severely affected lower leg skin for 30 min daily
Number of subjects: 0
Study 25703058 — intervention group
Group type: COMPARATOR
Intervention: Placebo control cuff
Number of subjects: 0
Study 23327604 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + NBM + PRP
Number of subjects: 24
Study 23327604 — intervention group
Group type: COMPARATOR
Intervention: EMD + NBM
Number of subjects: 24